Literature DB >> 25451981

Regulation of transcriptional activation function of rat estrogen receptor α (ERα) by novel C-terminal splice inserts.

Pallob Kundu1, Min Li2, Rong Lu2, Enrico Stefani3, Ligia Toro4.   

Abstract

Estrogen receptor α (ERα) mediates estrogen diverse actions on tissues. ERα gene has eight constitutively expressing exons and is known to have multiple isoforms generated by alternative initiation of transcription and splicing events including exon skipping. We have discovered two novel exons inserted between exon 5 and 6 of rat ERα that can add independently or in tandem 18 and 14 amino acids to the estrogen binding/activator function 2 domain of the receptor. Their transcript expression is three to six fold higher in heart compared to brain, aorta, liver, ovary and uterus. In heart, the new variants increased ~2 fold with animal growth from prenatal to adulthood, and had a minor increment in aged animals (28 months). Inclusion of these exons yields a receptor with practically no binding capacity for estrogen and reduced dimerization. The new variants show nuclear localization but are less efficient in binding to estrogen responsive elements (EREs) and failed to transcriptionally activate promoters containing EREs (mSlo, KCNE2). Thus, the new variants can regulate the wild-type receptor function and may contribute to the regulatory action of estrogen, especially in the maturing heart where they are more abundant.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alternative splicing; Estrogen receptor; Heart; Steroid receptor coactivator; Transcription regulation

Mesh:

Substances:

Year:  2014        PMID: 25451981      PMCID: PMC4312711          DOI: 10.1016/j.mce.2014.11.001

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  44 in total

1.  Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays.

Authors:  Jason M Johnson; John Castle; Philip Garrett-Engele; Zhengyan Kan; Patrick M Loerch; Christopher D Armour; Ralph Santos; Eric E Schadt; Roland Stoughton; Daniel D Shoemaker
Journal:  Science       Date:  2003-12-19       Impact factor: 47.728

2.  An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription.

Authors:  A Bollig; R J Miksicek
Journal:  Mol Endocrinol       Date:  2000-05

3.  Function of the exon 7 deletion variant estrogen receptor alpha protein in an estradiol-resistant, tamoxifen-sensitive human endometrial adenocarcinoma grown in nude mice.

Authors:  György Horvath; Gunilla Leser; Khalil Helou; Malin Henriksson
Journal:  Gynecol Oncol       Date:  2002-02       Impact factor: 5.482

4.  The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation.

Authors:  D M Lonard; Z Nawaz; C L Smith; B W O'Malley
Journal:  Mol Cell       Date:  2000-06       Impact factor: 17.970

5.  A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm.

Authors:  Rakesh Kumar; Rui-An Wang; Abhijit Mazumdar; Amjad H Talukder; Mahitosh Mandal; Zhibo Yang; Rozita Bagheri-Yarmand; Aysegul Sahin; Gabriel Hortobagyi; Liana Adam; Christopher J Barnes; Ratna K Vadlamudi
Journal:  Nature       Date:  2002-08-08       Impact factor: 49.962

6.  Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells.

Authors:  Hiroko Yamashita; Hirotaka Iwase; Tatsuya Toyama; Yoshitaka Fujii
Journal:  Oncogene       Date:  2003-03-20       Impact factor: 9.867

7.  Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.

Authors:  Véronique Marsaud; Angélique Gougelet; Sébastien Maillard; Jack-Michel Renoir
Journal:  Mol Endocrinol       Date:  2003-07-10

8.  Estrogen receptor-alpha messenger RNA variants that lack exon 5 or exon 7 are coexpressed with wild-type form in human endometrium during all phases of the menstrual cycle.

Authors:  Paul B Marshburn; Jian Zhang; Zahra Bahrani-Mostafavi; Behrooz Z Mostafavi; Marie-Claire Marroum; Jean-Luc C Mougeot; Michael J Roshon
Journal:  Am J Obstet Gynecol       Date:  2004-08       Impact factor: 8.661

9.  The naturally occurring variant of estrogen receptor (ER) ERDeltaE7 suppresses estrogen-dependent transcriptional activation by both wild-type ERalpha and ERbeta.

Authors:  Juana M García Pedrero; Pedro Zuazua; Carlos Martínez-Campa; Pedro S Lazo; Sofía Ramos
Journal:  Endocrinology       Date:  2003-07       Impact factor: 4.736

10.  KCNE2 protein is expressed in ventricles of different species, and changes in its expression contribute to electrical remodeling in diseased hearts.

Authors:  Min Jiang; Mei Zhang; Daniel G Tang; Henry F Clemo; Jie Liu; Dana Holwitt; Vigneshwar Kasirajan; Amber L Pond; Erich Wettwer; Gea-Ny Tseng
Journal:  Circulation       Date:  2004-04-05       Impact factor: 29.690

View more
  3 in total

1.  Functional characterization of tomato membrane-bound NAC transcription factors.

Authors:  Payel Bhattacharjee; Rohit Das; Arunava Mandal; Pallob Kundu
Journal:  Plant Mol Biol       Date:  2016-12-30       Impact factor: 4.076

Review 2.  Androgen and estrogen sensitivity of bird song: a comparative view on gene regulatory levels.

Authors:  Carolina Frankl-Vilches; Manfred Gahr
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2017-12-06       Impact factor: 1.836

Review 3.  Distribution and Effects of Estrogen Receptors in Prostate Cancer: Associated Molecular Mechanisms.

Authors:  Adrián Ramírez-de-Arellano; Ana Laura Pereira-Suárez; Cecilia Rico-Fuentes; Edgar Iván López-Pulido; Julio César Villegas-Pineda; Erick Sierra-Diaz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-11       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.